Sodium-glucose cotransporter inhibitors may reduce the risk of pneumonia: an updated meta-analysis of cardiovascular outcome trials

AbstractThe present meta-analysis included 8 cardiovascular outcome trials with 57,185 patients at high cardiometabolic risk. In comparison with placebo, treatment with sodium-glucose cotransporter inhibitors was associated with a significantly lower risk of pneumonia (RR 0.85, 95% CI 0.76 –0.95,p = 0.004;I2 = 0,p = 0.48).

http://link.springer.com/10.1007/s13340-021-00515-4

Source: Diabetology International - June 6, 2021 Category: Endocrinology Source Type: research